Egalet's 70% price increase shows the buy-and-hike strategy is alive and well

Drug prices
Egalet raised the price of a pain drug 70% after acquiring it from Iroko, according to researchers at 46brooklyn. (Getty/Tero Vesalainen)

Think the entire pharma industry has moved past the old strategy of buying drug rights, jacking up prices and reaping the rewards? Think again.

Big Pharma may be limiting hikes to the single digits, but some smaller drugmakers aren't shying away from the buy-and-hike strategy that's triggered public outrage in the past. Consider Egalet, which recently bought several pain meds from Iroko Pharmaceuticals and immediately filed for bankruptcy.

One day after closing the deal, Egalet boosted its price on one of those drugs, Zorvolex, by 70%,according to drug pricing researchers at 46brooklyn and a report from Axios.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

The drug now carries a list price of $650 per bottle containing 90 pills, Axios reports, citing Elsevier data. Last year, the same bottle cost $383, according to the publication. The prices are before rebates and discounts.

An Egalet representative said the drug's price is "now consistent with similarly differentiated branded products in its class."

To get its hands on the Iroko drugs and a phase 2 pipeline candidate, Egalet had issued Iroko $45 million in notes, handed over 49% of its new common stock and promised potential royalty payments. Now, the company projects $80 million to $90 million in annual sales from its entire portfolio.

RELATED: Tiny Egalet scouting for 60 reps to hawk its new pain meds 

Small drug companies have frequently turned to big price hikes in an effort to pump up sales, often leading to pushback from patients, payers and Congress. Most notoriously, Martin Shkreli’s Turing Pharma in 2015 boosted the price of toxoplasmosis drug Daraprim by 5,000%, setting off a drug pricing firestorm that’s still playing out years later.

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.